<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413296</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00007843</org_study_id>
    <secondary_id>7031-05-4R0</secondary_id>
    <nct_id>NCT00413296</nct_id>
  </id_info>
  <brief_title>Levetiracetam in Post-Traumatic Stress Disorder</brief_title>
  <acronym>PTSD</acronym>
  <official_title>A Double-Blind Discontinuation Study of Levetiracetam in Post- Traumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the short-term efficacy and safety of levetiracetam
      in post-traumatic stress disorder (PTSD) and to evaluate continuation effects of
      levetiracetam in preventing PTSD relapse. The hypothesis is that levetiracetam will be safe
      and effective in preventing relapse of PTSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator-initiated, single site study, consisting of two phases: 8 weeks of
      open label treatment with levetiracetam (500-2000 mg/day) in patients with PTSD, and in those
      who demonstrate at least minimal improvement, 12 weeks of randomized, double-blind treatment
      with either levetiracetam or matching placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impressions - Improvement (CGI-I)</measure>
    <time_frame>20 wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Davidson Trauma Scale (DTS)</measure>
    <time_frame>20 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>20 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connor-Davidson Resilience Scale (CD-RISC)</measure>
    <time_frame>20 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item Short Form Health Survey (SF-36)</measure>
    <time_frame>20 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>20 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Improvement Questionnaire (WPAI)</measure>
    <time_frame>20 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Inventory (SDI)</measure>
    <time_frame>20 wks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablets, no active ingredient, 1-6 tablets/day for 12 wks in the 2 nd phase of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levetiracetam, 500mg (1-6 tablets /day) for 12 wks in the 2nd phase of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levetiracetam</intervention_name>
    <description>Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetriracetam</intervention_name>
    <description>Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 18-65

          -  primary diagnosis of PTSD based on DSM-IV criteria and assessed by the MINI
             International Neuropsychiatric Interview (MINI)

          -  Davidson Trauma Scale (DTS) score of at least 40 on screening

          -  ability to provide written informed consent

        Exclusion Criteria:

          -  any primary DSM-IV Axis I disorder other than PTSD

          -  substance abuse during the last 6 months

          -  a clinically unstable medical condition or clinically significant laboratory
             abnormalities

          -  suicide risk or serious suicide attempt during the last year

          -  concurrent use of psychotropic medications including benzodiazepines, barbiturates,
             antiepileptic drugs, antidepressants, buspirone, dietary supplements or herbal or
             homeopathic remedies with psychotropic effects

          -  recent (within the last 3 months) initiation of cognitive behavioral therapy

          -  failure of a previous trial of levetiracetam at 2000 mg/day

          -  pregnancy or lactation

          -  women of childbearing potential who are unwilling to practice an acceptable method of
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Davidson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <last_update_submitted>July 18, 2014</last_update_submitted>
  <last_update_submitted_qc>July 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Pharmacotherapy</keyword>
  <keyword>Levetiracetam</keyword>
  <keyword>Relapse prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

